BioMeetingpoint at the Biotechnica

The Biotechnology Thematic Group (BioTG) of the IRC Network together with other European partners are organising again the BioMeetingpoint for companies, R&D organisations and stakeholders to hold bilateral meetings at Biotechnica Hannover, Europe's leading biotechnology trade fair, which will take place in Hannover, Germany 9 - 11 October 2007.

Since 1985 Biotechnica Hannover has been the most important trade show in Europe for biotechnology. For the BioMeetingpoint a catalogue of company profiles and technology offers and requests will be available electronically and will allow participating companies and organisations to organise their individual meetings in advance.

The BioMeetingpoint functions as an "interface between research and the private sector" allowing new technologies, processes, patents and licenses to be offered and experience in financing, production, marketing and distribution to be requested, thus bringing compatible partners together.

The BioMeetingpoint is the ideal environment for:

  • Enterprises offering and/or using innovative technologies.
  • Enterprises that are looking for expertise and know-how in the areas of production, marketing and distribution or wish to provide this knowledge to others.
  • Scientists and research institutes offering application-oriented research results.
  • Start-ups.
  • Investors.

They will have the opportunity to get to know selected partners during individual discussions, which aim to pave the way for future co-operations.

For further information, please visit:
http://www.biomeetingpoint.org

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...

Scientific evidence to date on COVID-19 vaccine ef…

An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe C...

How a plant virus could protect and save your lung…

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at...

COVID-19 nasal vaccine candidate effective at prev…

Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in develop...